Teladoc Stock News

Don''t Look Now, But Cathie Wood''s Ark Is Taking On Water Among the biggest losers over the last 48 hour tech stock volatility has beenwell, everything in Cathie Wood''s "flagship" ARKK portfolio. Ergo, Wood''s ARKK fund has continued its dismal year, looking as though it could be heading back toward double digits any day now. Key components of Cathie Wood''s ARKK fund, including Tesla, Zoom, Spotify and DraftKings, are all lower in trading on Tuesday. Tesla is down more than 5% and names like Spotify and DraftKings were also down more than 5% at their lows during the cash session. Astute observers online are also starting to point out what can only be described as a massively widening delta between ARKK and all major indexes - to the tune of a whopping 40%! How long can investors ignore numbers like these from their favorite "active manager" before funds begin a deluge out of the way of all things Cathie Wood? $ARKK -16% YTD $QQQ +26% YTD $SPY +25% YTD DR. LUCID (@DRLUCID520) November 23, 2021 In addition, Wood''s Ark Genomic Revolution ETF has also been suffering outflows in November as returns lag.

Teladoc Health (NYSE:TDOC) had its price objective reduced by analysts at Canaccord Genuity from $188.00 to $160.00 in a research report issued on Tuesday, The Fly reports. The brokerage presently has a buy rating on the health services providers stock. Canaccord Genuitys price objective points to a potential upside of 46.68% from the stocks previous []

Li Auto Inc. (LI) with the stream of 2.12% also noticed, India Teladoc Health, Inc. (TDOC) encountered a rapid change of -6.08% in the last hour of Mondays trading session. The post Analysts Report Recap: Li Auto Inc. (NASDAQ:LI), Teladoc Health, Inc. (NYSE:TDOC) appeared first on Stocks Equity .

BTIG Research lowered shares of Teladoc Health (NYSE:TDOC) from a buy rating to a neutral rating in a research note released on Monday, Price Targets.com reports. Other research analysts also recently issued research reports about the stock. Argus downgraded shares of Teladoc Health from a buy rating to a hold rating in a report on []

I did not invest in teledoc when it was reasonably priced , however, now might be an opportunity the only issue i have is that you have no ability to create a relationship with one doctor. you just get anyone, and for me thats a big problem was the spike in price partly linked with []

Berman Capital Advisors LLC boosted its stake in shares of Teladoc Health, Inc. (NYSE:TDOC) by 221.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 459 shares of the health services providers stock after acquiring an additional 316 shares during the quarter. Berman Capital []

Teladoc Health (NYSE:TDOC) had its price objective lowered by Stephens from $140.00 to $135.00 in a research note issued to investors on Friday morning, Price Targets.com reports. The brokerage currently has an equal weight rating on the health services providers stock. Several other equities research analysts also recently commented on TDOC. Oppenheimer reduced their price []

Teladoc Health (NYSE:TDOC) had its price target lowered by Credit Suisse Group from $208.00 to $207.00 in a report released on Friday, Price Targets.com reports. Credit Suisse Group currently has an outperform rating on the health services providers stock. A number of other research firms also recently weighed in on TDOC. Canaccord Genuity lowered their []

Metropolitan Life Insurance Co NY increased its position in shares of Teladoc Health, Inc. (NYSE:TDOC) by 43,228.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,033 shares of the health services providers stock after purchasing an additional 3,026 shares during the quarter. Metropolitan []

Teladoc Health (NYSE:TDOC) had its price objective decreased by equities research analysts at SVB Leerink from $205.00 to $193.00 in a research note issued on Friday, PriceTargets.com reports. The brokerage presently has an outperform rating on the health services providers stock. SVB Leerinks price target would indicate a potential upside of 64.97% from the stocks []